The DOI matches its Crossref record; 255 of the 256 references it cites were found in a registry or an index.
mRNA-based therapeutics--developing a new class of drugs
Open accessAbstract
In vitro transcribed (IVT) mRNA has recently come into focus as a potential new drug class to deliver genetic information. Such synthetic mRNA can be engineered to transiently express proteins by structurally resembling natural mRNA. Advances in addressing the inherent challenges of this drug class, particularly related to controlling the translational efficacy and immunogenicity of the IVTmRNA, provide the basis for a broad range of potential applications. mRNA-based cancer immunotherapies and infectious disease vaccines have entered clinical development. Meanwhile, emerging novel approaches include in vivo delivery of IVT mRNA to replace or supplement proteins, IVT mRNA-based generation of pluripotent stem cells and genome engineering using IVT mRNA-encoded designer nucleases. This Review provides a comprehensive overview of the current state of mRNA-based drug technologies and their applications, and discusses the key challenges and opportunities in developing these into a new class of drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mRNA vaccines still suffer from decreased efficacy due to poor RNA stability in solution and in vivo and to limited expression of the payload mRNA; these are all pivotal issues that need to be carefully optimized for preclinical and clinical applications3–6.”
From Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, we focused on ψ and m1ψ, since these substitutions for U have been widely adopted for mRNA therapeutics and vaccines due to improved in-cell translation and to better control of innate immune responses2,3,8,67 through avoidance of recognition by cellular toll-like receptors (TLR7 and TLR8)68, RIG‑I, and PKR69–71.”
From Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IVT is a low-cost method of mRNA synthesis; however the immunogenicity of mRNA is the most challenging obstacle it faces (Sahin et al. 2014).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The 3ʹ-UTRs of α- and β-globin mRNAs are found in many in vitro-transcribed (IVT) mRNA, and they contain sequence features that enhance the translation and stability of mRNA (Sahin et al. 2014; Karikó et al. 1999).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“The 7-methylguanosine (m7G) moiety is found at the 5′ end of natural mRNA in the eukaryotic cytoplasm, followed by a triphosphate connection to the first nucleotide (m7GpppN) (Sahin et al. 2014).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“The basic structure of mRNA, same as eukaryotic mRNA, is made up of (i) protein encoding ORF, surrounded by (ii) 5′ and 3′ UTRs, and (iii) a 7-methyl guanosine 5′ cap structure and (iv) a 3′poly(A) tail at the end sides (Verbeke et al. 2019; Schlake et al. 2012; Sahin et al. 2014) (Fig. 1).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“The 3ʹ-UTRs of α- and β-globin mRNAs are found in many in vitro-transcribed (IVT) mRNA, and they contain sequence features that enhance the translation and stability of mRNA (Sahin et al. 2014; Karikó et al. 1999).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“IVT is a low-cost method of mRNA synthesis; however the immunogenicity of mRNA is the most challenging obstacle it faces (Sahin et al. 2014).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
In the citing paper
“Since the 3′-OH group in proximity to m7G is methylated, thus the ARCA cap analog can only bind the 5′ end of mRNA in forward orientation, which is recognized by the eukaryotic translation initiation factor 4E (eIF4E) to initiate ribosome recruitment and translation.74,125”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [74]
In the citing paper
“The host immune system can easily recognize unmodified mRNA or by-products formed during IVT of engineered mRNA as exogenous molecules.74”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [74]
In the citing paper
“Tfh cells recognize antigens on the APC surface and help to activate B cells, which in turn produce high-affinity virus-neutralizing antibodies.6,55, 56, 57”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [57]
In the citing paper
“Tfh cells further help activate CD8+ cytotoxic T cells that may specifically recognize and eliminate virus-infected cells (Figure 1).6,55, 56, 57”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [57]
In the citing paper
“mRNA has shown therapeutic potential in a range of applications, including viral vaccines, protein replacement therapies, cancer immunotherapies, cellular reprogramming and genome editing2,4,7–17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“These elements can be engineered to improve the stability and translational efficiency of mRNA2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“mRNA is susceptible to degradation and, thus, formulation buffers should be free of any ribonuclease contaminations2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“mRNA normally contains five structural elements, that is, a 5′ cap, a 3′ poly(A) tail, a protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Chromatographic purification can remove double-stranded RNA, an analogue of viral genome, in IVT mRNA preparations, diminishing immune activation and increasing translational efficiency2,4,7,183.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Many other lipid nanoparticle–mRNA formulations are in clinical trials for the treatment of infectious diseases, cancer and genetic disorders2,4,8,12–14 (Tables 1,2).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Chemical modifications of specific IVT mRNA nucleotides, such as pseudouridine (ψ) and N1-methylpseudouridine (m1ψ), can reduce innate immune sensing of exogenous mRNA translation2,4,7,182.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“To address these concerns, the engineering of mRNA molecules (Box 1) and the design of lipid nanoparticles have been optimized2,4,7–17, which has contributed to the rapid development and clinical assessment15,17 of the two COVID-19 mRNA vaccines, mRNA-1273 (NCT04470427)19,20 and BNT162b2 (NCT04368728)21.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Finally, GMP-grade lipid nanoparticle-mRNA vaccines can be manufactured for specific antigens in a short period of time, compared with other vaccine platforms, such as recombinant proteins and inactivated vaccines2,4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Moreover, mRNA-based cellular reprogramming, tissue regeneration and genome editing have shown therapeutic potential in preclinical studies2,4,8,12–14.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Compared with regular mRNA, self-amplifying RNA (also termed replicon), which was originally derived from an alphavirus genome, has similar basic elements (5′ cap, 5′ and 3′ untranslated regions, 3′ poly(A) tail) and a long coding region.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“After delivery into the cytoplasm, self-amplifying RNA (positive-strand mRNA) functions as a translation template for the production of the RDRP.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“The coding region contains the sequences for an RNA-dependent RNA polymerase (RDRP), a promoter and structural viral proteins (also known as subgenomic sequence).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Meanwhile, the promoter in the negative-strand RNA is recognized by the RDRP, leading to the transcription of capped subgenomic RNA that encodes structural viral proteins.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“This self-amplification process allows the mass production of virions from limited amounts of virus at infection.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Replacing the subgenomic sequence by a gene of interest enables high-level expression of desired proteins.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“The initial replication leads to negative-strand RNA, which acts as template for the generation of the positive-strand viral genome.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“The transient replication generates double-stranded RNA (dsRNA) and, thus, self-amplifying RNA tends to activate innate immune pathways.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Moreover, the positive-strand mRNA serves as a genomic template for RDRP-mediated replication.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“To achieve effective translation, mRNA requires five structural elements, including the 5′ cap, 3′ poly(A) tail, protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“The sequences of these elements regulate translation initiation, translation termination and post-transcriptional modification of mRNA molecules2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“mRNA functions as the bridge between DNA and proteins in eukaryotic cells.[8, 12, 119]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [119]
In the citing paper
“Compared with protein drugs, mRNA can supplement both cytoplasmic and large transmembranic proteins.[8, 119, 120]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [119]
In the citing paper
“Relative to plasmid DNA (pDNA), mRNA possesses temporary bioactivity and functions outside the nucleus, leading to a more controllable protein expression and avoiding the potential insertion of the genome.[8, 119, 120]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [119]
In the citing paper
“Protein-encoding mRNA has emerged as an attractive new technology for gene delivery.1”
From Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening (2019) · cites this paper as [1]
In the citing paper
“Robust induction of an immune response by a cancer vaccine requires efficient expression of the vaccine antigen-encoding mRNA specifically in DCs to achieve a high density of epitope-loaded MHCs.1,42”
From Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening (2019) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., & Fujita, T. (2004) · Nature Immunology · doi:10.1038/ni1087 · Cited by 4,022
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Flagged first, then by citations
1 of the 256 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Prieels, J.-P. et al. Mastering industrialization of cell therapy products. BioProcess Int. 10, S12–S15 (2012).
Cited by
Sorted by citations
Items 401–500 of 1,005
Efficient Colorectal Cancer Gene Therapy with IL-15 mRNA Nanoformulation
Lei, S., Zhang, X., Men, K., Gao, Y., Yang, X., Wu, S., Duan, X., Wei, Y., & Tong, R. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00451 · Cited by 83
Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
Mansanguan, S., Charunwatthana, P., Piyaphanee, W., Dechkhajorn, W., Poolcharoen, A., & Mansanguan, C. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7080196 · Cited by 83
Testing thousands of nanoparticles in vivo using DNA barcodes
Lokugamage, M. P., Sago, C. D., & Dahlman, J. E. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.08.001 · Cited by 84
Small-molecule-based regulation of RNA-delivered circuits in mammalian cells
Wagner, T. E., Becraft, J. R., Bodner, K., Teague, B. P., Zhang, X., Woo, A. R. E., Porter, E. B., Alburquerque, B., Dobosh, B. S., Andries, O., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0146-9 · Cited by 83
Verbeke, R., Lentacker, I., Breckpot, K., Janssens, J., Calenbergh, S. V., Smedt, S. C. D., & Dewitte, H. (2019) · ACS Nano · doi:10.1021/acsnano.8b07660 · Cited by 85
Highly Efficient Transfection of Human Primary T Lymphocytes Using Droplet-Enabled Mechanoporation
Joo, B., Hur, J., Kim, G.-B., Yun, S. G., & Chung, A. J. (2021) · ACS Nano · doi:10.1021/acsnano.0c10473 · Cited by 81
An update of anti-viral treatment of COVID-19
Yavuz, S. Ş., & Celikyurt, I. K. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2106-250 · Cited by 88
Amphiphilic Dendrimer Vectors for RNA Delivery: State-of-the-Art and Future Perspective
Chen, J., Zhu, D., Liu, X., & Peng, L. (2022) · Accounts of Materials Research · doi:10.1021/accountsmr.1c00272 · Cited by 84
Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery
Mollé, L. M., Smyth, C. H., Yuen, D., & Johnston, A. P. R. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1809 · Cited by 95
RNA delivery biomaterials for the treatment of genetic and rare diseases
Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82
Structurally Programmed Assembly of Translation Initiation Nanoplex for Superior mRNA Delivery
Li, J., Wang, W., He, Y., Li, Y., Yan, E. Z., Zhang, K., Irvine, D. J., & Hammond, P. T. (2017) · ACS Nano · doi:10.1021/acsnano.6b08447 · Cited by 82
Engineering Gene Therapy: Advances and Barriers
Shahryari, A., Burtscher, I., Nazari, Z., & Lickert, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100040 · Cited by 87
Clinical development and approval of COVID-19 vaccines
Kalinke, U., Barouch, D. H., Rizzi, R., Lagkadinou, E., Türeci, Ö., Pather, S., & Neels, P. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2042257 · Cited by 86
Self-citationmRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics
Chavda, V. P., Soni, S., Vora, L. K., Soni, S., Khadela, A. D., & Ajabiya, J. (2022) · Vaccines · doi:10.3390/vaccines10122150 · Cited by 89
Chimeric antigen receptor therapy meets mRNA technology
Wu, J., Wu, W., Zhou, B., & Li, B. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.08.005 · Cited by 86
Fleming, A. M., Mathewson, N. J., Manage, S. A. H., & Burrows, C. J. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00788 · Cited by 78
Jiang, T., Yu, N., Kim, J., Murgo, J.-R., Kissai, M., Ravichandran, K. R., Miracco, E. J., Presnyak, V., & Hua, S. S. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b01664 · Cited by 82
COVID-19 in Human, Animal, and Environment: A Review
Swelum, A. A., Shafi, M. E., Albaqami, N. M., El‐Saadony, M. T., Elsify, A. M., Abdo, M., Taha, A. E.-S., Abdel‐Moneim, A. E., Al-Gabri, N. A., Almaiman, A. A., et al. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.00578 · Cited by 83
Bialkowski, L., van Weijnen, A., der Jeught, K. V., Renmans, D., Daszkiewicz, L., Heirman, C., Stangé, G. M., Breckpot, K., Aerts, J. L., & Thielemans, K. (2016) · Scientific Reports · doi:10.1038/srep22509 · Cited by 79
Cella, F., Wróblewska, L., Weiss, R., & Siciliano, V. (2018) · Nature Communications · doi:10.1038/s41467-018-06825-7 · Cited by 78
mRNA vaccines: the most recent clinical applications of synthetic mRNA
Kwon, S., Kwon, M., Im, S., Lee, K., & Lee, H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01381-7 · Cited by 85
Emerging delivery approaches for targeted pulmonary fibrosis treatment
Diwan, R., Bhatt, H., Beaven, E., & Nurunnabi, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115147 · Cited by 81
Yang, T., Li, C., Wang, X., Zhao, D., Zhang, M., Cao, H., Liang, Z., Xiao, H., Liang, X., Weng, Y., et al. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.07.003 · Cited by 78
Moradian, H., Roch, T., Anthofer, L., Lendlein, A., & Gossen, M. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.004 · Cited by 77
Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development
Schmidt, C., & Schnierle, B. S. (2023) · Pathogens · doi:10.3390/pathogens12010138 · Cited by 78
Viral and Synthetic RNA Vector Technologies and Applications
Schott, J. W., Morgan, M., Galla, M., & Schambach, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.143 · Cited by 76
Liu, G., Carter, B., Bricken, T., Jain, S., Viard, M., Carrington, M. N., & Gifford, D. K. (2020) · Cell Systems · doi:10.1016/j.cels.2020.06.009 · Cited by 75
Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery
Żak, M. M., & Zangi, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101675 · Cited by 75
Camperi, J., Lippold, S., Ayalew, L., Roper, B., Shao, S., Freund, E. C., Nissenbaum, A., Galan, C., Cao, Q., Yang, F., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c05539 · Cited by 76
Steinle, H., Behring, A., Schlensak, C., Wendel, H. P., & Avci‐Adali, M. (2016) · Stem Cells · doi:10.1002/stem.2402 · Cited by 78
Barrett, P. N., Terpening, S. J., Snow, D. M., Cobb, R. R., & Kistner, O. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1357471 · Cited by 77
Dirisala, A., Uchida, S., Tockary, T. A., Yoshinaga, N., Li, J., Osawa, S., Gorantla, L., Fukushima, S., Osada, K., & Kataoka, K. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1550646 · Cited by 76
Moradian, H., Roch, T., Lendlein, A., & Gossen, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60506-4 · Cited by 77
Intracellular Delivery of mRNA in Adherent and Suspension Cells by Vapor Nanobubble Photoporation
Raes, L., Stremersch, S., Fraire, J. C., Brans, T., Goetgeluk, G., Munter, S. D., Hoecke, L. V., Verbeke, R., Hoeck, J. V., Xiong, R., et al. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00523-0 · Cited by 76
Cao, Y., He, Z., Chen, Q., He, X., Su, L., Yu, W., Zhang, M., Yang, H., Huang, X., & Li, J. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c01784 · Cited by 73
Zha, W., Wang, J., Guo, Z., Zhang, Y., Wang, Y., Dong, S., Liu, C., Xing, H., & Li, X. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122565 · Cited by 77
mRNA therapeutics: New vaccination and beyond
Wei, H. Y., Zheng, L., & Wang, Z. (2023) · Fundamental Research · doi:10.1016/j.fmre.2023.02.022 · Cited by 77
Inagaki, M., Abe, N., Li, Z., Nakashima, Y., Acharyya, S., Ogawa, K., Kawaguchi, D., Hiraoka, H., Banno, A., Meng, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38244-8 · Cited by 80
Light‐Activated Control of Translation by Enzymatic Covalent mRNA Labeling
Zhang, D., Zhou, C. Y., Busby, K. N., Alexander, S. C., & Devaraj, N. K. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201710917 · Cited by 74
Wei, G., Cao, J., Huang, P., An, P., Skelton-Badlani, D., Vaid, K. A., Zhao, S., Wang, D. Q. ‐., Zhuo, J., Yin, L., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.010 · Cited by 74
Advances in Nanoparticles for Effective Delivery of RNA Therapeutics
Byun, M. J., Lim, J., Kim, S.-N., Park, D.-H., Kim, T. P., Park, W., & Park, C. G. (2022) · BioChip Journal · doi:10.1007/s13206-022-00052-5 · Cited by 78
mRNA vaccines: Past, present, future
Karam, M., & Daoud, G. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.05.003 · Cited by 76
Lipid nanoparticle-mediated mRNA delivery in lung fibrosis
Massaro, M., Wu, S., Baudo, G., Liu, H., Collum, S. D., Lee, H., Stigliano, C., Segura-Ibarra, V., Karmouty‐Quintana, H., & Blanco, E. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106370 · Cited by 77
The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology
Ye, Z., Harmon, J., Ni, W., Li, Y., Wich, D., & Xu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12584 · Cited by 72
tRNA therapeutics for genetic diseases
Coller, J., & Ignatova, Z. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00829-9 · Cited by 72
Selective gene expression maintains human tRNA anticodon pools during differentiation
Gao, L., Behrens, A., Rodschinka, G., Forcelloni, S., Wani, S., Strasser, K., & Nedialkova, D. D. (2024) · Nature Cell Biology · doi:10.1038/s41556-023-01317-3 · Cited by 78
Recent Advances and Prospects in RNA Drug Development
Tani, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212284 · Cited by 78
RNA Therapeutics - Research and Clinical Advancements
Feng, R., Patil, S., Zhao, X., Miao, Z., & Qian, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.710738 · Cited by 75
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Chabanovska, O., Galow, A.-M., David, R., & Lemcke, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114002 · Cited by 81
Gene editing therapeutics based on mRNA delivery
Popovitz, J., Sharma, R. K., Hoshyar, R., Kim, B. S., Murthy, N., & Lee, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115026 · Cited by 73
mRNA-based therapeutics–Advances and perspectives
Sergeeva, O. V., Koteliansky, V., & Zatsepin, T. S. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916070075 · Cited by 74
A “top-down” approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery
Jiang, Y., Gaudin, A., Zhang, J., Agarwal, T., Song, E., Kauffman, A. C., Tietjen, G. T., Wang, Y., Jiang, Z., Cheng, C. J., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.043 · Cited by 72
Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding
Jarrell, J. A., Twite, A. A., Lau, K. H. W. J., Kashani, M. N., Lievano, A. A., Acevedo, J., Priest, C., Nieva, J. J., Gottlieb, D. J., & Pawell, R. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-40147-y · Cited by 72
Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates
Tan, L., Zheng, T., Li, M., Zhong, X., Tang, Y., Qin, M., & Sun, X. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00725-4 · Cited by 73
Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors
Ye, T., Li, F., Ma, G., & Wei, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113927 · Cited by 73
Zhao, Y., Wei, K., Chi, H., Xia, Z., & Li, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022808 · Cited by 71
Montano, D. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2021.756633 · Cited by 70
Perkembangan Teknologi Terkini dalam Mempercepat Produksi Vaksin COVID-19
Sari, I. P., & Sriwidodo, S. (2020) · Majalah Farmasetika · doi:10.24198/mfarmasetika.v5i5.28082 · Cited by 70
Delivery of therapeutic oligonucleotides in nanoscale
Wu, L., Zhou, W., Lin, L., Chen, A., Feng, J. C., Qu, X., Zhang, H., & Yue, J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.05.038 · Cited by 72
mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
Ouranidis, A., Vavilis, T., Mandala, E., Davidopoulou, C., Stamoula, Ε., Markopoulou, C. K., Karagianni, A., & Kachrimanis, K. (2021) · Biomedicines · doi:10.3390/biomedicines10010050 · Cited by 75
Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design
Clemente, B., Denis, M., Silveira, C. P., Schiavetti, F., Brazzoli, M., & Stranges, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294929 · Cited by 71
Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma
Tang, X., Zhang, S., Fu, R., Zhang, L., Huang, K., Peng, H., Dai, L., & Chen, Q. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01208 · Cited by 69
Schrom, E., Huber, M., Aneja, M., Dohmen, C., Emrich, D., Geiger, J., Hasenpusch, G., Herrmann-Janson, A., Kretzschmann, V., Mykhailyk, O., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.006 · Cited by 69
Recent advances in mRNA vaccine delivery
Tan, L., & Sun, X. (2018) · Nano Research · doi:10.1007/s12274-018-2091-z · Cited by 71
Uebbing, L., Ziller, A., Siewert, C., Schroer, M. A., Blanchet, C. E., Svergun, D. I., Ramishetti, S., Peer, D., Şahin, U., Haas, H., et al. (2020) · Langmuir · doi:10.1021/acs.langmuir.0c02446 · Cited by 68
Geng, J., Xia, X., Teng, L., Wang, L., Chen, L., Guo, X., Belingon, B., Li, J., Feng, X., Li, X., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.032 · Cited by 70
Domestic Animals as Potential Reservoirs of Zoonotic Viral Diseases
Tomori, O., & Oluwayelu, D. O. (2023) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-062922-060125 · Cited by 79
Feng, Z., Zhang, X., Zhou, J., Li, Q., Chu, L., Di, G., Xu, Z., Chen, Q., Wang, M., Jiang, X., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00650-8 · Cited by 70
Treating Cystic Fibrosis with mRNA and CRISPR
Sanchez, A. D. S., Paunovska, K., Cristian, A., & Dahlman, J. E. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.137 · Cited by 75
Pérez-Núñez, I., Rozalén, C., Palomeque, J. Á., Sangrador, I., Dalmau, M., Comerma, L., Hernández‐Prat, A., Casadevall, D., Menéndez, S., Liu, D. D., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00339-4 · Cited by 65
A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs
Bogaert, B., Sauvage, F., Guagliardo, R., Muntean, C., Nguyen, V. P., Pottie, E., Wels, M., Minnaert, A., Rycke, R. M. D., Yang, Q., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.009 · Cited by 69
The Delivery of mRNA Vaccines for Therapeutics
Nitika, Wei, J., & Hui, A. (2022) · Life · doi:10.3390/life12081254 · Cited by 71
Gong, L., Zhang, Y., Zhu, Y., Lee, U., Luo, A. C., Li, X., Wang, X., Chen, D., Pu, W. T., Lin, R., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.05.014 · Cited by 73
Chen, S., Zaifman, J., Kulkarni, J. A., Zhigaltsev, I. V., Tam, Y. K., Ciufolini, M. A., Tam, Y. Y. C., & Cullis, P. R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.026 · Cited by 68
Strzelecka, D., Śmietański, M., Sikorski, P. J., Warmiński, M., Kowalska, J., & Jemielity, J. (2020) · RNA · doi:10.1261/rna.077099.120 · Cited by 68
Dirisala, A., Uchida, S., Li, J., Guyse, J. F. R. V., Hayashi, K., Vummaleti, S. V. C., Kaur, S., Mochida, Y., Fukushima, S., & Kataoka, K. (2022) · Macromolecular Rapid Communications · doi:10.1002/marc.202100754 · Cited by 67
Delivering mRNA to Secondary Lymphoid Tissues by Phosphatidylserine‐Loaded Lipid Nanoparticles
Gomi, M., Sakurai, Y., Sato, M., Tanaka, H., Miyatake, Y., Fujiwara, K., Watanabe, M., Shuto, S., Nakai, Y., Tange, K., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202202528 · Cited by 68
mRNA: A promising platform for cancer immunotherapy
Kong, B., Kim, Y., Kim, E. H., Suk, J. S., & Yang, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114993 · Cited by 74
Hashiba, A., Toyooka, M., Sato, Y., Maeki, M., Tokeshi, M., & Harashima, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.031 · Cited by 66
Perspectives on RNA Vaccine Candidates for COVID-19
Borah, P., Deb, P. K., Al‐Shar’i, N. A., Dahabiyeh, L. A., Venugopala, K. N., Singh, V., Shinu, P., Hussain, S., Deka, S., Chandrasekaran, B., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.635245 · Cited by 67
Fierro, C. A., Brune, D., Shaw, M., Schwartz, H., Knightly, C., Lin, J., Carfı́, A., Natenshon, A., Kalidindi, S., Bouteiller-Reuter, C., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae114 · Cited by 66
Supramolecular interaction in the action of drug delivery systems
Geng, W.-C., Jiang, Z.-T., Chen, S., & Guo, D. (2024) · Chemical Science · doi:10.1039/d3sc04585d · Cited by 71
Self-Replicating RNA Viruses for RNA Therapeutics
Lundstrom, K. H. (2018) · Molecules · doi:10.3390/molecules23123310 · Cited by 66
Fan, Y., Yen, C., Lin, H.-C., Hou, W., Estevez, A., Sarode, A., Goyon, A., Bian, J., Lin, J., Koenig, S. G., et al. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120392 · Cited by 68
Recent advances in biomaterial-boosted adoptive cell therapy
Xue, Y., Che, J., Ji, X., Li, Y., Xie, J., & Chen, X. S. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00786f · Cited by 70
An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
Bayani, F., Hashkavaei, N. S., Arjmand, S., Rezaei, S., Uskoković, V., Alijanianzadeh, M., Uversky, V. N., Siadat, S. O. R., Mozaffari‐Jovin, S., & Sefidbakht, Y. (2023) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2023.02.004 · Cited by 67
Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy
Yi, K., Kong, H., Lao, Y., Li, D., Mintz, R. L., Fang, T., Chen, G., Tao, Y., Li, M., & Ding, J. (2023) · Advanced Materials · doi:10.1002/adma.202300665 · Cited by 66
Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines
Russell, C. A., Fouchier, R. A. M., Ghaswalla, P. K., Park, Y., Vicic, N., Ananworanich, J., Nachbagauer, R., & Rudin, D. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2336357 · Cited by 69
pH‐Responsive β‐Glucans‐Complexed mRNA in LNPs as an Oral Vaccine for Enhancing Cancer Immunotherapy
Luo, P.-K., Ho, H., Chiang, M., Chu, L., Chuang, Y., Lyu, P. C., Hu, I., Chang, W.-A., Peng, S., Jayakumar, J., et al. (2024) · Advanced Materials · doi:10.1002/adma.202404830 · Cited by 65
Serum Nuclease Susceptibility of mRNA Cargo in Condensed Polyplexes
Yen, A., Cheng, Y., Sylvestre, M., Gustafson, H. H., Puri, S., & Pun, S. H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00134 · Cited by 69
Wang, Y., Wu, Q., Wang, J., Li, L., Sun, X., Zhang, Z., & Zhang, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.024 · Cited by 65
CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy
Richardson, J. R., Schöllhorn, A., Gouttefangeas, C., & Schuhmacher, J. (2021) · Cancers · doi:10.3390/cancers13040596 · Cited by 66
Exploring the epitranscriptome by native RNA sequencing
Begik, O., Mattick, J. S., & Novoa, E. M. (2022) · RNA · doi:10.1261/rna.079404.122 · Cited by 65
Hybrid modeling for biopharmaceutical processes: advantages, opportunities, and implementation
Narayanan, H., von Stosch, M., Feidl, F., Sokolov, M., Morbidelli, M., & Butté, A. (2023) · Frontiers in Chemical Engineering · doi:10.3389/fceng.2023.1157889 · Cited by 65
Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development
Andersson, S., Antonsson, M., Elebring, M., Jansson‐Löfmark, R., & Weidolf, L. O. G. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.030 · Cited by 64
Non-viral strategies for delivering genome editing enzymes
Li, J., Røise, J. J., He, M., Das, R., & Murthy, N. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.004 · Cited by 63
Strenkowska, M., Grzela, R., Majewski, M., Wnek, K., Kowalska, J., Łukaszewicz, M., Zuberek, J., Darżynkiewicz, E., Kuhn, A. N., Şahin, U., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw896 · Cited by 63
RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions
MacLeod, A. R., & Crooke, S. T. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.957 · Cited by 61
Latest Development on RNA-Based Drugs and Vaccines
Lundstrom, K. H. (2018) · Future Science OA · doi:10.4155/fsoa-2017-0151 · Cited by 65
Investigation of charge ratio variation in mRNA – DEAE-dextran polyplex delivery systems
Siewert, C., Haas, H., Nawroth, T., Ziller, A., Nogueira, S. S., Schroer, M. A., Blanchet, C. E., Svergun, D. I., Rădulescu, A., Bates, F., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.020 · Cited by 65
Metadata
- Authors
- Sahin, U., Karikó, K., & Türeci, Ö.
- Affiliations
- BioNTech (Germany) (DE)
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Karikó, Katalin
- Türeci, Özlem
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-09-19
- Volume
- 13
- Issue
- 10
- Pages
- 759-780
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1963706689
- Cited by
- 2,474
- References
- 256
- Citations by year
- 2026: 296 · 2025: 348 · 2024: 341 · 2023: 312 · 2022: 339 · 2021: 289 · 2020: 143 · 2019: 115 · 2018: 98 · 2017: 81 · 2016: 77 · 2015: 32 · 2014: 2
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- in vitro transcribed mRNA, mRNA therapeutics, mRNA vaccines, cancer immunotherapy, protein replacement therapy, genome editing, designer nucleases, immunogenicity, biopharmaceutical development
- MeSH terms
- Animals, Humans, Immunotherapy, Proteins, RNA, Messenger, Drug Design, Drug Delivery Systems, Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
